Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial.
Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé JB, Carrou JL, Kouame GM, Ouattara E, Messou E, Anzian A, Minga A, Gnokoro J, Gouesse P, Emieme A, Toni TD, Rabe C, Sidibé B, Nzunetu G, Dohoun L, Yao A, Kamagate S, Amon S, Kouame AB, Koua A, Kouamé E, Daligou M, Hawerlander D, Ackoundzé S, Koule S, Séri J, Ani A, Dembélé F, Koné F, Oyebi M, Mbakop N, Makaila O, Babatunde C, Babatunde N, Bleoué G, Tchoutedjem M, Kouadio AC, Sena G, Yededji SY, Karcher S, Rouzioux C, Kouame A, Assi R, Bakayoko A, Domoua SK, Deschamps N, Aka K, N'Dri-Yoman T, Salamon R, Journot V, Ahibo H, Ouassa T, Menan H, Inwoley A, Danel C, Eholié SP, Anglaret X; Temprano ANRS 12136 Study Group.
Badje A, et al. Among authors: salamon r.
Lancet Glob Health. 2017 Nov;5(11):e1080-e1089. doi: 10.1016/S2214-109X(17)30372-8.
Lancet Glob Health. 2017.
PMID: 29025631
Free article.
Clinical Trial.